Australia markets close in 5 hours 3 minutes

Allergy Therapeutics plc (AGY.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
2.6500-0.2000 (-7.02%)
At close: 04:35PM BST
Currency in GBp

Valuation measures4

Market cap (intra-day) 126.31M
Enterprise value 122.64M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.85
Price/book (mrq)4.77
Enterprise value/revenue 2.30
Enterprise value/EBITDA -3.14

Trading information

Stock price history

Beta (5Y monthly) 1.34
52-week change 3-57.60%
S&P500 52-week change 320.07%
52-week high 36.2500
52-week low 30.0000
50-day moving average 32.6780
200-day moving average 32.3278

Share statistics

Avg vol (3-month) 3667.94k
Avg vol (10-day) 3650.74k
Shares outstanding 54.77B
Implied shares outstanding 64.85B
Float 8105.67M
% held by insiders 193.21%
% held by institutions 10.12%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -94.29%
Operating margin (ttm)-34.15%

Management effectiveness

Return on assets (ttm)-34.76%
Return on equity (ttm)-155.90%

Income statement

Revenue (ttm)53.26M
Revenue per share (ttm)0.03
Quarterly revenue growth (yoy)-15.90%
Gross profit (ttm)N/A
EBITDA -37M
Net income avi to common (ttm)-50.22M
Diluted EPS (ttm)-0.0600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)13.52M
Total cash per share (mrq)0
Total debt (mrq)9.85M
Total debt/equity (mrq)37.22%
Current ratio (mrq)1.40
Book value per share (mrq)0.01

Cash flow statement

Operating cash flow (ttm)-32.2M
Levered free cash flow (ttm)-17.3M